Cipla Revs Up In US, Newer Markets To Cushion Against Volatility

US scale-up plans, cost optimization and a deeper push in certain other markets to garner volumes and as a buffer against volatility were some of the key strategies discussed by Cipla’s CEO at the recent J.P. Morgan Healthcare Conference in San Francisco.

Jigsaw — CIPLA ANTICIPATES A BUILD UP IN ITS US BUSINESS

Momentum in ANDA filings, building on the base of limited competition complex generics and specialty products in the US, and a hawk eye on costs were among the key themes presented by the senior management of Indian firm Cipla Ltd. at the J.P. Morgan Healthcare Conference in San Francisco.

Cipla’s managing director and global CEO, Umang Vohra, outlined the company’s ongoing efforts to grow the US business towards a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Stock Watch: Pharma Financial Forecasts Cannot Withstand Headwinds Forever

15 Jul 2025

• By Andy Smith

Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.

Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

15 Jul 2025

• By Jung Won Shin

Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

14 Jul 2025

• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

14 Jul 2025

• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Takeda Prepares Ground For Oveporexton In Narcolepsy

14 Jul 2025

• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.